{
    "clinical_study": {
        "@rank": "102660", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A: DCV 3DAA FDC fasted state", 
                "arm_group_type": "Experimental", 
                "description": "DCV 3 Direct Acting Antiviral (DAA) Fixed Dose Combination (FDC) tablet by mouth once on specified days in fasted state"
            }, 
            {
                "arm_group_label": "Treatment B: DCV 3DAA FDC with high-fat meal", 
                "arm_group_type": "Experimental", 
                "description": "DCV 3DAA FDC tablet by mouth once on specified days with high-fat meal"
            }, 
            {
                "arm_group_label": "Treatment C: DCV 3DAA FDC with light meal", 
                "arm_group_type": "Experimental", 
                "description": "DCV 3DAA FDC tablet by mouth once on specified days with light meal"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the effect of a high fat meal and light meal on the\n      blood levels of Daclatasvir, Asunaprevir and BMS-791325 after administration of the 3 drugs\n      as a fixed-dose combination in healthy subjects."
        }, 
        "brief_title": "Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "detailed_description": {
            "textblock": "IND Number: 100,932/79,599/101,943\n\n      Primary Purpose:\n\n      Other: Phase 1 clinical pharmacology bioavailability study to assess food effect"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Healthy male and female subjects ages 18 to 49 years, inclusive.\n\n          -  Women of childbearing potential must be using an acceptable method of contraception\n             for at least 4 weeks prior to study drug administration.\n\n        Exclusion Criteria:\n\n          -  Any significant acute or chronic medical illness\n\n          -  Current or recent (within 3 months of study drug administration) gastrointestinal\n             disease\n\n          -  Any gastrointestinal surgery that could impact upon the absorption of study drug,\n             including cholecystectomy\n\n          -  History of biliary disorders, including Gilbert's syndrome or Dubin-Johnson disease\n\n          -  Use of tobacco-containing or nicotine-containing products\n\n          -  Any of the following on 12-lead electrocardiogram (ECG) prior to study drug\n             administration, confirmed by repeat:\n\n               -  PR \u2265210 msec\n\n               -  QRS \u2265120 msec\n\n               -  QT \u2265500 msec\n\n               -  QTcF \u2265450 msec\n\n          -  Any of the following laboratory results outside of the ranges specified below prior\n             to study drug administration, confirmed by repeat:\n\n               -  Alanine aminotransferase (ALT) >Upper limit of normal (ULN)\n\n               -  Aspartate aminotransferase (AST) >ULN\n\n               -  Total bilirubin (TBILI) >ULN\n\n               -  Creatinine >ULN"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "49 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02095860", 
            "org_study_id": "AI443-111"
        }, 
        "intervention": {
            "arm_group_label": [
                "Treatment A: DCV 3DAA FDC fasted state", 
                "Treatment B: DCV 3DAA FDC with high-fat meal", 
                "Treatment C: DCV 3DAA FDC with light meal"
            ], 
            "description": "Fixed Dose Combination of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325", 
            "intervention_name": "DCV 3DAA FDC", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 7, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": {
            "contact": {
                "last_name": "Emanuel Denoia, Site 0001"
            }, 
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78209"
                }, 
                "name": "Healthcare Discoveries, Llc D/B/A Icon Development Solutions"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open-label, Randomized, Crossover Study to Assess the Effect of Food on the Pharmacokinetics of Daclatasvir, Asunaprevir, and BMS-791325 Following Administration of a Single Fixed Dose Combination of DCV 3DAA FDC in Healthy Subjects", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of the email MUST contain NCT# and Site #."
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum observed plasma concentration (Cmax) of DCV, ASV and BMS-791325", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 13"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of DCV, ASV and BMS-791325", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 13"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02095860"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] for DCV, ASV and BMS-791325", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 13"
            }, 
            {
                "measure": "Time of maximum observed plasma concentration (Tmax) for DCV, ASV and BMS-791325", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 13"
            }, 
            {
                "measure": "Terminal plasma half life (T-HALF) for DCV, ASV and BMS-791325", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 13"
            }, 
            {
                "measure": "AUC(0-T) for BMS-794712", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 13"
            }, 
            {
                "measure": "AUC(INF) for BMS-794712", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 13"
            }, 
            {
                "measure": "Cmax for BMS-794712", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 13"
            }, 
            {
                "measure": "Tmax for BMS-794712", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 13"
            }, 
            {
                "measure": "T-HALF for BMS-794712", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 13"
            }, 
            {
                "measure": "Safety measured by incidence of adverse event (AEs), serious AEs (SAEs) and AEs leading to discontinuation", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to Day 13"
            }, 
            {
                "measure": "Safety measured by abnormalities in vital sign measurements", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to Day 13"
            }, 
            {
                "measure": "Safety measured by findings on electrocardiograms (ECG) measurements and physical examinations", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to Day 13"
            }, 
            {
                "measure": "Safety measured by marked abnormalities in clinical laboratory test results", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to Day 13"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}